Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An Assessment of Biological Potency and Molecular Characteristics of Different Innovator and Noninnovator Interferon-Beta Products

7 Dec 2010

Abstract excerpt

Approved innovator products and their noninnovator "copy" versions are likely to vary in their quality, eg, physicochemical characteristics and biological activity, with important implications for clinical efficacy and safety. Therefore, it is important to study and thoroughly evaluate the noninnovator products in comparison with approved products at the preclinical and clinical stages. We have obtained 4...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Multiple Sclerosis Research Studies
Share to Systemic Lupus Erythematosus Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21138379
DOI: 10.1089/jir.2010.0113

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Assessment of Biological Potency and Molecular Characteristics of Different Innovator and Noninnovator Interferon-Beta ProductsPMID 21138379Read ↗

Immunopharmacological consequences of immune responses to therapeutic interferon betaSemantic proximity Read ↗

Biological and biosimilar medicinal products: safety and efficacySemantic proximity Read ↗

Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylationSemantic proximity Read ↗

Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changesSemantic proximity Read ↗

Characterization and comparability of biosimilars: A filgrastim case of study and regulatory perspectives for Latin AmericaSemantic proximity Read ↗

Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).Semantic proximity Read ↗

Cytokines--protein structure and biological activity: a complex relationship with implications for biological assays and standardization.Semantic proximity Read ↗

Novel long-lasting interferon alpha derivatives designed by glycoengineering.Semantic proximity Read ↗

Physicochemical and biologic properties of interferons and their potential uses in drug delivery systems.Semantic proximity Read ↗

Interferon-alpha hybrids.Semantic proximity Read ↗

Carboxy-terminal truncated rhuIFN-gamma with a substitution of Gln133 or Ser132 to leucine leads to higher biological activity than in the wild type.Semantic proximity Read ↗

Improved sandwich enzyme-linked immunosorbent assays for transforming growth factor β1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.